A new study has broken the hopes that a combination of aspirin and another clot-preventing drug might be a better alternative for preventing strokes in people with the abnormal heart rhythm called as ‘atrial fibrillation’ than the standard therapy, of warfarin.
Canadian researchers have cut short their study after the preliminary results showed that there is a higher incidence of not only of strokes, but also of minor bleeding episodes, in people taking the combination of aspirin and clopidogrel (Plavix), They reported their findings in a report in the June 10 issue of The Lancet.
It was explained that warfarin, an anticoagulant, is effective for preventing clotting and strokes in patients, but is was very hard to manage. Dr. Stuart Connelly, director of the division of cardiology at McMaster University, in Hamilton, Ontario, the study leader said that this trial does not create any new indications for clopidogrel, he explained that atrial fibrillation might cause blood to pool in the heart, that could encourage the formation of clots that can then travel to the brain to cause stroke.
Even though warfarin is a powerful anti-clotting agent the doctors world over have always tried to find and use an alternative. The patients using warfarin had to take frequent blood tests to make sure that the dosage is precisely right, due to the high risk of major bleeding episodes is always present. It was explained that the management of the treatment with warfarin is very difficult.